| Literature DB >> 35925268 |
Marcel Wiesweg1,2, Wilfried E Eberhardt3,4, Martin Schuler3,4, Till Plönes5.
Abstract
Treatment concepts for patients with localized and locally advanced non-small cell lung cancer (NSCLC) are based on local treatment, surgery and/or radiotherapy, with curative intent. An adjuvant systemic treatment is added after primary resection of an operable NSCLC primarily to reduce the systemic risk of relapse. Locally advanced stages with mediastinal lymph node involvement carry a substantial risk of local and distant recurrence and require multimodal treatment strategies in an interdisciplinary approach. Recently, immunotherapy with programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) checkpoint inhibitors is increasingly being integrated into adjuvant, neoadjuvant or perioperative treatment concepts.Entities:
Keywords: Chemotherapy, adjuvant; Combined modality therapy; Immune checkpoint inhibitors; Immunotherapy, preoperative; Radiotherapy, adjuvant
Mesh:
Year: 2022 PMID: 35925268 DOI: 10.1007/s00108-022-01366-0
Source DB: PubMed Journal: Inn Med (Heidelb) ISSN: 2731-7080